NEWS FROM THE LITERATURE


1.a FEAST to read if you want to know about c-KIT inhibitors

Melanoma Research:

December 2011 - Volume 21 - Issue 6 - p 475–482

doi: 10.1097/CMR.0b013e32834b58cf

Review Article

Mucosal melanomas of the head and neck: new aspects of the clinical outcome, molecular pathology, and treatment with c-kit inhibitors

Papaspyrou, Giorgios^a; Garbe, Claus^b; Schadendorf, Dirk^c; Werner, Jochen A.^a; Hauschild, Axel^d; Egberts, Friederike^d

--------------------------------------------------------------------------------------------------------
2. TALKING FYN  gene AGAIN

"Dasatinib, at nanomolar concentrations, inhibits the following kinases: BCR-ABL, SRC family (SRC, LCK, YES, FYN), c-KIT, EPHA2, and PDGFRβ. Based on modeling studies, dasatinib is predicted to bind to multiple conformations of the ABL kinase."(FROM THE MANUFACTURER)
aND i BET YOU YOU DOUBTED ME WHEN I TOLD YOU FYN WAS A "CRAZY GENE"
ADD IT TO THE MIXT AND YOU GOT YOURSELF A GREAT DRUG!
-----------------------------------------------------------------------------------
3.FOR LUNG CANCER
Always obtain EGFR, ALK, ROS1,
KRAS remains controversial although it has been used as a surrogate for :

• Death With Dignity Program Well Accepted by Cancer Patients
• Preventing Heart Damage From Chemotherapy: OVERCOME Trial
• Mutation Status May Guide Treatment for HER2 Breast Cancer
• Doctors Fail to Counsel Lung Cancer Patients to Quit Smoking

Medscape Oncology > Viewpoints

KRAS+ Lung Cancer Responds to Targeted Therapy

H. Jack West, MD

DisclosuresFeb 13, 2013

Editors' Recommendations

• Common Lung Cancer Mutation Responds to Targeted Treatment
• Finally, a Treatment for Most Common Lung Cancer Mutation

Selumetinib Plus Docetaxel for KRAS-Mutant Advanced Non-Small-Cell Lung Cancer: A Randomised, Multicentre, Placebo-Controlled, Phase 2 Study

Jänne PA, Shaw AT, Pereira JR, et al